Literature DB >> 25957334

Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.

Nikolai Pfender1, Ilijas Jelcic1, Michael Linnebank1, Urs Schwarz1, Roland Martin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25957334      PMCID： PMC4464745          DOI： 10.1212/WNL.0000000000001659

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin
Journal:  Lancet Neurol       Date:  2014-03-28       Impact factor: 44.182

2.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

3.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

4.  T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Authors:  Meret E Ricklin; Johannes Lorscheider; Anne Waschbisch; Cecile Paroz; Satish K Mehta; Duane L Pierson; Jens Kuhle; Bettina Fischer-Barnicol; Till Sprenger; Raija L P Lindberg; Ludwig Kappos; Tobias Derfuss
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

5.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910
  5 in total
  19 in total

Review 1.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 3.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

Review 4.  Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Clin Microbiol Rev       Date:  2020-02-12       Impact factor: 26.132

5.  Cerebral Venous Thrombosis due to Cryptococcus in a Multiple Sclerosis Patient on Fingolimod.

Authors:  Joel A Kammeyer; Nicole M Lehmann
Journal:  Case Rep Neurol       Date:  2022-06-24

6.  Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections.

Authors:  Evgeny Berdyshev; Elena Goleva; Irina Bronova; Anna Sofia Bronoff; Joanne E Streib; Kathryn A Vang; Brittany N Richers; Patricia Taylor; Lisa Beck; Miguel Villarreal; Keli Johnson; Gloria David; Mark K Slifka; Jon Hanifin; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2022-03-15       Impact factor: 14.290

Review 7.  Sphingosine 1-phosphate receptor modulators in multiple sclerosis.

Authors:  Adnan M Subei; Jeffrey A Cohen
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 8.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

9.  HSV-2-related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS.

Authors:  Kazuhiro Ikumi; Tetsuo Ando; Harutaka Katano; Masahisa Katsuno; Yu Sakai; Mari Yoshida; Takahiko Saida; Hiroshi Kimura; Gen Sobue
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-06-07

10.  Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.

Authors:  Rozita Doosti; Abdorreza Naser Moghadasi; Amir Reza Azimi; Shahrokh Karbalai Saleh; Masoud Etemadifar; Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Hossein Harirchian; Seyed Bahaadin Siroos; Hormoz Ayramloo; Nastaran Majdinasab; Seyyed Mohammad Masood Hojjati; Nabiollah Asghari; Seyed Mohammad Baghbanian; Hamed Cheraghmakani; Mahmoud Abedini; Behnaz Sedighi; Negar Mohseni Abbas Abadi; Maedeh Ghasemitabar; Sara Talebianpour; Tohid Babayi Daylari; Vahid Dana; Neda Ghaleh Noie; Mohammad Ali Sahraian
Journal:  Caspian J Intern Med       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.